Search
Vedolizumab
go.drugbank.com/drugs/DB09033ApprovedInvestigational[A261576] Vedolizumab is administered by IV infusion over a period of 30 minutes; after the first dose, it is given again at two and six weeks and then every 8 weeks thereafter. … Vedolizumab is a recombinant humanized IgG1 monoclonal antibody directed against the human lymphocyte α4β7 integrin, a key mediator of gastrointestinal inflammation implicated in diseases like ulcerative
Products: ENTYVIO SC, ENTYVIO® 108 MG SOLUCIÓN INYECTABLEPembrolizumab
go.drugbank.com/drugs/DB09037ApprovedInvestigationalPembrolizumab is a highly selective IgG4-kappa humanized monoclonal antibody against PD-1 receptors. … It was generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody onto a human IgG4-kappa isotype containing a stabilizing S228P Fc mutation.
Categories: PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors, PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitorsProducts: Keytruda Sc, KEYTRUDA SCAlbiglutide
go.drugbank.com/drugs/DB09043ApprovedInvestigationalWithdrawnAlbiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). … It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on April 15, 2014 by the FDA.
Categories: Glucagon-like peptide-1 (GLP-1) analogues, GLP-1 AgonistsNaloxegol
go.drugbank.com/drugs/DB09049ApprovedInvestigationalNaloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. … It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 InhibitorsSynonyms: (5α,6α)-17-Allyl-6-[(20-hydroxy-3,6,9,12,15,18-hexaoxaicos-1-yl)oxy]-4,5-epoxymorphinan-3,14-diolBlinatumomab
go.drugbank.com/drugs/DB09052ApprovedInvestigational[A254836,L44311] CD3 is an antigen expressed on the surface of T-cells, while CD19 is mostly expressed on the surface of malignant B-cells. … a short peptide linker.
Categories: Bispecific CD19-directed CD3-directed T Cell EngagerProducts: BLINCYTO® 38.5 MCG/VIAL, BLİNCYTO 38,5 MCG İNFÜZYONLUK ÇÖZELTİ İÇİN KONSANTRE TOZ VE ÇÖZELTİ, 1 ADETAcipimox
go.drugbank.com/drugs/DB09055ApprovedInvestigationalAcipimox is a niacin derivative used as a hypolipidemic agent. … It is used in low doses and may have less marked adverse effects, although it is unclear whether the recommended dose is as effective as are standard doses of nicotinic acid.
Categories: Heterocyclic Compounds, 1-RingAnthrax immune globulin human
go.drugbank.com/drugs/DB09057ApprovedInvestigationalAnthrax immune globulin is a human antibody given with antibiotics for the treatment of anthrax. … It is derived from the plasma of humans immunized with BioThrax (adsorbed anthrax vaccine), which is then further purified.
Corifollitropin alfa
go.drugbank.com/drugs/DB09066ApprovedInvestigationalMultiple studies and a meta-analysis suggest that corifollitropin alfa is as efficacious as recombinant FSH in terms of live birth rate, ongoing pregnancy rate, as well as clinical pregnancy rate. … Corifollitropin alfa is marketed as Elonva in more than 75 countries [L2272]. Corifollitropin alfa is produced by a method known as ‘recombinant DNA technology’.
Products: GONAL-F ® 300 UI (22 MCG)/0.5 ML INYECTOR (FOLITROPINA ALFA (R-HFSH)), GONAL -F ® INYECTOR 450 UI (33MCG)/0.75ML.Olaparib
go.drugbank.com/drugs/DB09074ApprovedInvestigationalOlaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2. … [A246015] Olaparib is used to treat a number of BRCA-associated tumours, including ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer.
Categories: MATE 2-K Inhibitors, P-glycoprotein substrates with a Narrow Therapeutic IndexSynonyms: 4-(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorobenzyl)phthalazin-1(2H)-oneEdoxaban
go.drugbank.com/drugs/DB09075ApprovedInvestigationalEdoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. … It is indicated to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF) and for the treatment of deep vein thrombosis (DVT) and pulmonary embolism
Categories: P-glycoprotein substrates, Heterocyclic Compounds, 1-Ring